Literature DB >> 19919819

5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines.

K Ishii1, M Zaitsu, N Yonemitsu, Y Kan, Y Hamasaki, M Matsuo.   

Abstract

OBJECTIVE: 5-lipoxygenase (5-LO) is a key enzyme in the synthesis of leukotrienes (LTs), that might promote carcinogenesis. We investigated 5-LO expression and examined whether the 5-LO pathway is associated with the proliferation of human brain tumors.
METHODS: We immunohistochemically evaluated the profile of 5-LO expression in various types of brain tumors obtained from 42 patients, and examined the proliferative effects of the 5-LO pathway in human glioma cell lines using a proliferation assay.
RESULTS: Immunohistochemistry of glioblastomas, astrocytomas, meningiomas, medulloblastomas, craniopharyngiomas, ependymomas, neurinomas, oligodendrogliomas, malignant lymphomas, dysembryoplastic neuroepithelial and metastatic brain tumors revealed 5-LO expression in the cytoplasm and nuclei or nuclear envelopes of tumor cells. The 5-LO inhibitor A861 and the LTA4 hydrolase inhibitor Bestatin dose-dependently suppressed the proliferation of A172 cells, a glioma cell line.
CONCLUSIONS: We confirmed the expression of 5-LO in various human brain tumors and demonstrated the partial suppression of tumor growth by inhibitors of the 5-LO-LTA4 hydrolase pathway in human glioma cell lines. The 5-LO-LTA4 pathway might play roles in the proliferation of human glioma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919819     DOI: 10.5414/npp28445

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  15 in total

1.  Well-differentiated liposarcoma of the oesophagus: clinicopathological, immunohistochemical and array CGH analysis.

Authors:  Jae Kyung Myung; Ji Bong Jeong; Daehee Han; Chi Sung Song; Hyeon Jong Moon; Young A Kim; Ji Eun Kim; Sun-Ju Byun; Woo Ho Kim; Mee Soo Chang
Journal:  Pathol Oncol Res       Date:  2010-10-31       Impact factor: 3.201

2.  Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population.

Authors:  Tian-Bo Jin; Xiao-Lan Li; Hua Yang; Mutu Jiri; Xu-Gang Shi; Dong-Ya Yuan; Long-Li Kang; Shan-Qu Li
Journal:  Med Oncol       Date:  2013-09-05       Impact factor: 3.064

3.  An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells.

Authors:  Bin Wang; Shi-cang Yu; Jian-yong Jiang; Gavin Wallace Porter; Lin-tao Zhao; Zhe Wang; Hong Tan; You-hong Cui; Cheng Qian; Yi-fang Ping; Xiu-wu Bian
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.

Authors:  Xingfu Wang; Yupeng Chen; Sheng Zhang; Lifeng Zhang; Xueyong Liu; Li Zhang; Xiaoling Li; Dayang Chen
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

5.  Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro.

Authors:  Undurti N Das; N Madhavi
Journal:  Lipids Health Dis       Date:  2011-09-14       Impact factor: 3.876

Review 6.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

Review 7.  Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis.

Authors:  Italo Mario Cesari; Erika Carvalho; Mariana Figueiredo Rodrigues; Bruna Dos Santos Mendonça; Nivea Dias Amôedo; Franklin David Rumjanek
Journal:  Int J Cell Biol       Date:  2014-02-06

8.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

9.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23

10.  Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation.

Authors:  Qiaoping Wang; Haiyan Li; Zhen Sun; Lihua Dong; Ling Gao; Chunlan Liu; Xiujie Wang
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.